Sunshine Biopharma (SBFM) Depreciation & Amortization (CF) (2016 - 2025)
Sunshine Biopharma's Depreciation & Amortization (CF) history spans 11 years, with the latest figure at $98581.0 for Q4 2025.
- For Q4 2025, Depreciation & Amortization (CF) rose 50.74% year-over-year to $98581.0; the TTM value through Dec 2025 reached $332070.0, up 48.56%, while the annual FY2025 figure was $332070.0, 48.56% up from the prior year.
- Depreciation & Amortization (CF) reached $98581.0 in Q4 2025 per SBFM's latest filing, up from $96163.0 in the prior quarter.
- In the past five years, Depreciation & Amortization (CF) ranged from a high of $98581.0 in Q4 2025 to a low of $789.0 in Q3 2022.
- Average Depreciation & Amortization (CF) over 5 years is $37132.4, with a median of $36042.0 recorded in 2023.
- Peak YoY movement for Depreciation & Amortization (CF): tumbled 75.21% in 2022, then skyrocketed 4614.83% in 2023.
- A 5-year view of Depreciation & Amortization (CF) shows it stood at $3184.0 in 2021, then surged by 496.01% to $18977.0 in 2022, then soared by 123.18% to $42353.0 in 2023, then soared by 54.41% to $65399.0 in 2024, then surged by 50.74% to $98581.0 in 2025.
- Per Business Quant, the three most recent readings for SBFM's Depreciation & Amortization (CF) are $98581.0 (Q4 2025), $96163.0 (Q3 2025), and $72533.0 (Q2 2025).